Biochips Market Outlook:
Biochips Market size was valued at USD 14.27 billion in 2025 and is set to exceed USD 45.12 billion by 2035, registering over 12.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of biochips is evaluated at USD 15.84 billion.
The market growth is driven by increasing occurrence of immunodeficiency disorders among people across the world. For instance, more than 7 million persons worldwide were suffering from primary immunodeficiencies by 2021, with around 75 to 93% remaining untreated. Also, there are around 430 different primary immunodeficiencies or primary immunodeficiency disorders (PIDs) that have been discovered to date. Further, rapidly rising adoption of biochips in various research fields, such as genomics, drug discovery, and proteomics, will fuel the market demand.
In addition, the market revenue is propelled by rise in the need to develop novel vaccines through extensive medical research, backed by amplified funding in medical R&D activities across the globe. For instance, in 2019, the pharmaceutical industry in the United States invested more than USD 85 billion in research and development activities. These costs covered a wide range of operations, including medication research and testing, incremental enhancements including product expansions, and medical studies for safety monitoring. Additionally, increasing advances in the Lab-on-a-chip offerings along with the biomedical progression for microfluidic-based devices are predicted to boost the market expansion.
